# SARS-Cov-2 publication data repository

This is a data repository to support the main publication 

> "Virtual high-throughput screening inverse docking of highly active repurpose
  drugs against SARS-CoV-2". S. Ribone, S. A. Paz, C. F. Abrams, M. Villareal.
  XXXXXXXXXX, XX (2021) XX. doi: XXXXX

# Content

Inside `hards` folder you can find the scripts used to obtain by the high
active repurpoused drugs (HARDs) list following the procedure explained in the
main publication.

In folder `hards/output_27/` you can find the HARDs lists and other data
obtained from this scripts.

# Reference and License

The data distributed in `hards/output_27/` folder is extracted from ChEMBL
database. 

> ChEMBL data is from http://www.ebi.ac.uk/chembl - the version of ChEMBL is
  chembl_27.

> The data content in ChEMBL is licensed under a highly permissive Creative
  Commons license - specifically the "CC Attribution-ShareAlike 3.0 Unported
  license", see LICENSE file.

Primary current citation of ChEMBL data is:

> Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP,
  Mosquera JF, Mutowo P, Nowotka M, Gordillo-Marañón M, Hunter F, Junco L,
  Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux CJ, Segura-Cabrera
  A, Hersey A, Leach AR. ChEMBL: towards direct deposition of bioassay data.
  Nucleic Acids Res. 2019 47(D1):D930-D940. DOI: 10.1093/nar/gky1075

A copy of the "CC Attribution-ShareAlike 3.0 Unported license" file can be
found in `hards/chembl_27/LICENSE`. See also `chembl_27/README` and
`chembl_27/REQUIRED.ATTRIBUTION` for further information.

The data extracted from ChEMBL comes from the following references:

> "Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human
  (Caco-2) cells using a large scale drug repurposing collection".  Ellinger et
  al.Research Square Preprint Platform (2020). DOI 10.21203/rs.3.rs-23951/v1

> "Identification of potential treatments for COVID-19 through artificial
  intelligence-enabled phenomic analysis of human cells infected with
  SARS-CoV-2." Heiser et al. bioRxiv (2020). DOI: 10.1101/2020.04.21.054387

> "In vitro screening of a FDA approved chemical library reveals potential
  inhibitors of SARS-CoV-2 replication." Touret et al. Scientific Reports
  (2020).  DOI: 10.1038/s41598-020-70143-6

Scripts in `hards/` are covered by a `BSD 2-Clause` License. See
`hards/LICENSE` file.

Please cite this repository and the main publication as:

> "Virtual high-throughput screening inverse docking of highly active repurpose
  drugs against SARS-CoV-2". S. Ribone, S. A. Paz, C. F. Abrams, M. Villareal.
  XXXXXXXXXX, XX (2021) XX. doi: XXXXX



